Semax and Selank: What the Research Shows

Semax and Selank are two synthetic peptides developed in Russia that are often discussed together in nootropic and wellness circles. This guide explains what each one is, what the research actually shows, what remains unknown, and where US regulation stands in 2026. It is educational and is not medical advice.

Key takeaways

• Both are synthetic seven-amino-acid peptides (heptapeptides) developed at Russian research institutions.
• Human evidence for each is limited: studies are small and short, and many were published only in Russian.
• No clinical trial has tested Semax and Selank together.
• Neither is FDA-approved in the US. Semax's compounding status is changing, and Selank's status could not be verified in public reporting.

What is Semax?

Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It was designed to keep ACTH's neurotrophic effects without its hormonal activity, and it was developed at the Russian Academy of Sciences. In Russia it is used for conditions such as stroke and dyscirculatory encephalopathy, and it is usually given intranasally.

What does the research on Semax show?

In animal studies, intranasal Semax has been linked to increased levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor in regions such as the hippocampus and frontal cortex. In one rat study the BDNF effect was seen at three hours but not at 24 hours.

Human evidence is thin. A pilot study of 24 healthy volunteers reported that intranasal Semax increased resting fMRI signal in part of the default mode network compared with placebo. Two small stroke studies, available mainly as Russian-language abstracts, reported better neurological recovery and, in one 110-patient study, higher plasma BDNF alongside better rehabilitation timing. Reviews note that well-conducted studies are lacking, and there is no evidence that Semax helps with Alzheimer's disease.

What is Selank?

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, a natural peptide involved in immune function, with added proline residues to make it more stable. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is reported to be approved in Russia for generalized anxiety disorder and neurasthenia.

What does the research on Selank show?

Proposed mechanisms include positive allosteric modulation of GABA-A receptors, effects on serotonin metabolism, and slowing the breakdown of enkephalins. Much of this comes from animal and laboratory work rather than human trials.

Human studies are small and short, often lasting weeks to months, and the key papers are in Russian, which makes their methods hard for Western reviewers to assess. There are no large Western randomized controlled trials, and no formal studies of interactions with psychiatric medications.

Why are Semax and Selank discussed together?

Semax has been studied for cognitive and neurotrophic effects, while Selank has been studied for anxiety. Some people pair them hoping for focus with a calmer baseline. That pairing is a hypothesis, not an established protocol: no clinical trial has evaluated the combination, and interactions are unknown. Anyone considering either peptide should talk to a licensed clinician first.

Safety and unknowns

• Long-term safety data for both peptides is lacking, and drug interactions are not well studied.
• Reported side effects, mostly anecdotal and mostly with intranasal use, include nasal irritation, headache, dizziness and fatigue.
• No effective dose has been established in well-designed human trials.
• Products sold as "research use only" may not be tested for purity or sterility.
• People who are pregnant or breastfeeding, or who take psychiatric medication, should speak with a clinician before considering any peptide.

Are Semax and Selank legal in the US?

Neither peptide is FDA-approved for any medical use in the United States. The regulatory picture for compounding has been moving in 2026:

• On April 15, 2026, the FDA announced it was removing 12 peptides, including Semax, from its Category 2 list of substances that raise significant safety concerns.
• On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 5 to recommend adding Semax to the 503A bulk drug substances list.
• Those votes are not binding. The FDA has not yet amended the list, formal rulemaking is still required, and legal commentators advise pharmacies not to treat the votes as authorization to begin compounding.
• Selank does not appear in public reporting on these actions, so its status should be confirmed directly with a pharmacist or regulatory attorney.

This area is changing quickly. Check current FDA guidance and your state's rules rather than relying on any single article, including this one.

Frequently asked questions

Are Semax and Selank the same thing?

No. Both are synthetic heptapeptides developed in Russia, but they come from different parent molecules: Semax from ACTH and Selank from tuftsin. Research on Semax centers on cognition and neuroprotection, and research on Selank centers on anxiety.

Is Semax FDA-approved?

No. Semax is not FDA-approved for any use in the US. In 2026 the FDA removed it from Category 2 and an advisory committee recommended adding it to the 503A bulks list, but those steps do not make it an approved drug.

Can you take Semax and Selank together?

There are no clinical trials of the combination, so its safety and effects are unknown. Talk to a licensed clinician before combining any compounds.

What is Selank used for?

In Russia, Selank is reported to be approved for generalized anxiety disorder and neurasthenia. In the US it is not FDA-approved for any use.

Is the research on these peptides reliable?

It is promising but limited. Much of it is preclinical, and the human studies are small, short and often available only in Russian. Larger, independent trials would be needed to confirm the findings.

Sources

• Alzheimer's Drug Discovery Foundation: Semax, Cognitive Vitality for Researchers
• Frier Levitt: FDA to Remove 12 Popular Peptides from the Category 2 List
• McDermott+: PCAC backs majority of peptides in two-day public meeting
• Buchanan Ingersoll & Rooney: FDA voted yes on six peptides, now what?
• Dr. Lewis: Selank for Anxiety (clinic overview, secondary source)

This article is for educational purposes only and is not medical advice. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure or prevent any disease. Consult a licensed healthcare provider before starting any treatment.